Progyny, Inc. (NASDAQ:PGNY) Shares Acquired by Wells Fargo & Company MN

Wells Fargo & Company MN boosted its holdings in Progyny, Inc. (NASDAQ:PGNY) by 37.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 39,593 shares of the company’s stock after acquiring an additional 10,856 shares during the quarter. Wells Fargo & Company MN’s holdings in Progyny were worth $683,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in PGNY. GAMMA Investing LLC lifted its position in shares of Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock valued at $28,000 after acquiring an additional 1,246 shares in the last quarter. Signaturefd LLC raised its stake in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after purchasing an additional 1,355 shares during the period. Nisa Investment Advisors LLC lifted its holdings in shares of Progyny by 108.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock valued at $51,000 after purchasing an additional 1,526 shares in the last quarter. KBC Group NV boosted its position in shares of Progyny by 84.6% in the fourth quarter. KBC Group NV now owns 4,669 shares of the company’s stock worth $81,000 after buying an additional 2,140 shares during the period. Finally, Entropy Technologies LP grew its holdings in shares of Progyny by 5.5% during the fourth quarter. Entropy Technologies LP now owns 47,883 shares of the company’s stock valued at $826,000 after buying an additional 2,499 shares in the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Down 0.2 %

Shares of PGNY opened at $22.80 on Friday. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of 39.31, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The company’s fifty day moving average is $21.89 and its 200-day moving average is $19.24. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $33.84.

Wall Street Analysts Forecast Growth

PGNY has been the subject of several research analyst reports. Canaccord Genuity Group increased their price objective on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th. BTIG Research raised shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target for the company in a research report on Monday, March 31st. JPMorgan Chase & Co. raised their price target on shares of Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, Bank of America upped their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.